Current Issue : October-December Volume : 2024 Issue Number : 4 Articles : 4 Articles
The current study focused on the production of sweet lozenges with the goal of enhancing bioavailability. To examine whether there were any interactions between the medications and the different formulation components, FT-IR was used and no interactions were found. Resveratrol lozenges were made by combining different polymers, such as HPMC K4M and Chitin, in various ratios. The prepared lozenges had an average weight of 2.16±0.006 to 3.08±0.004 gram, a percent friability of 1.86±0.008 to 2.14±0.003, a hardness of 10.15±0.004 to 12.27±0.003 kg/cm2, a disintegration time of 23.35±0.007 to 24.25±0.0012 minutes, a percent drug content of 96.5±0.006 to 99.4±0.005 and a percent moisture content in the range of 0.5±0.015 to 0.8±0.026 of based on all of the assessment factors, ZL2 was chosen as the optimal formulation. The in-vitro drug release was carried out in phosphate buffer with a pH of 6.8 and it was discovered that the drug release is dependent on the polymer concentration. The improved formulation ZL2's drug release kinetics were most closely related to zero order kinetics and the Korsmeyer-peppas drug release mechanism. The stability assessment of the improved formulation reveals no major changes in the product. According to the aforementioned findings, the influence of polymers such as HPMC K4M exhibits superior results in heat congealing method for the manufacturing of lozenges....
The purpose of this work was to develop an oral dispersible film of repaglinide utilizing pullulan as a polymer and analyze it using various criteria. Drug-excipient tests were conducted utilizing fourier transmission infrared spectroscopy (FT-IR) to identify potential incompatibilities. The oral dispersible films were created utilizing the solvent casting process with Pullulan as the polymer. Polyoxyethylene was employed as a plasticiser. The produced films were assessed for physical appearance, thickness, folding durability, in-vitro disintegration, mechanical characteristics, surface pH, drug content homogeneity, taste assessment, in-vitro dissolution test and stability analysis. The T6 formulation was determined to be more optimised, stable and adequate in terms of assessment parameters than other formulations. The folding endurance was 282±1.59, disintegration time was 05±0.57, thickness was 0.064±0.001, tensile strength was 5.89, % elongation was 26.08 and maximal drug release was 95.90% in 30 minutes. The drug content was determined to be 99.90, with a surface pH of 6.4. The formulation's stability experiments revealed that the product remained stable for 90 days. The oral dispersible film is simple to give and extremely successful for patients and the created film of repaglinide is a promising option for safe and effective oral dispersible drug administration....
This study aimed to enhance the dissolution rate and bioavailability of the poorly water-soluble drug raloxifene hydrochloride (RLX) by developing a stable nanosuspension-loaded buccal patch. RLX nanosuspension was formulated using high pressure homogenization, with Tween 20 and Poloxamer 188 as stabilizers. The nanosuspension was characterized for size distribution, zeta potential and morphology. The optimized nanosuspension was then incorporated into a buccal patch, which was prepared using a mucoadhesive layer and a backing membrane composed of ethyl cellulose/Eudragit RL100 via solvent casting. The resulting buccal patch was evaluated for physical, mechanical, bioadhesive properties, as well as in-vitro and in-vivo parameters. The RLX nanosuspension showed a particle size of 416.8 nm, a PDI of 0.256 and a zeta potential of +4.89 mV, with 86.955% drug release in-vitro. The nanosuspension-loaded buccal patch exhibited a particle size of 481.7 nm, a thickness of 0.173 mm and a weight of 0.163±0.004 g. It showed excellent folding endurance (>250), a surface pH of 6.63 and a swelling index of 255.30±0.19% at 6 hours. In-vitro drug release was 78.7±0.1% within 6 hours and the mucoadhesion strength was 13.5±0.10 g. In-vivo studies in a rat model revealed a 349.91% increase in relative bioavailability compared to the RLX suspension, likely due to bypassing gastrointestinal degradation and first-pass hepatic metabolism. Prepared RLX nanosuspension-loaded buccal patch significantly improves bioavailability and offers potential for drugs vulnerable to gastrointestinal degradation and first-pass metabolism....
The goal of the study was to create a proliposomal version of the NSAID medication flurbiprofen. Proliposomes were made utilizing the vacuum rotatory evaporator thin-film hydration approach, which included varying amounts of mannitol, phospholipid and cholesterol. A preformulation study was conducted to produce stable liposomes free of aggregation, fusion and sedimentation. Thin-film hydration was used to manufacture flurbiprofen proliposomes, which were found to be effective in producing liposomes that did not aggregate. The amount of cholesterol, phospholipid and aspartame was crucial for proliposome production and stabilization. Liposome vesicle size and dispersion were critical parameters for optimal results. A positive association was found between phospholipid and cholesterol, indicating that an increase in phospholipid and cholesterol content increased the size of the vesicles. Entrapment efficiency was found to be a crucial factor in liposomes, with entrapment efficiency ranging from 85.12 to 96.5%. Formulations F4-F9 exhibited the highest vesicle size and entrapment effectiveness, with flurbiprofen content ranging from 86.4% to 96.8%. Formulations F4, F1, F5 and F6 had peak drug content. The percentage yield results varied between 86.5±0.265 and 95.4±0.221 percent. When compared to pure medication, the in-vitro experiments showed that proliposomal gel formulation displays enhanced skin permeability exhibiting sustain release....
Loading....